Tosk’s current drug discovery and development efforts focus on applying the OMD technology to discover cancer chemotherapeutic side-effect-reducing agents (Company Web Page, Tosk, MAR 25, 2015, View Source [SID:1234502520]). The first applications of the technology are for the widely used chemotherapeutics, methotrexate, doxorubicin, and bleomycin. Tosk’s most advanced drug, TK-112690 for mucositis side effect reduction, has recently completed the first phase of human clinical testing

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!